Rephonic
Artwork for Hematologic Oncology Update

Hematologic Oncology Update

Dr. Neil Love
Multiple Myeloma
Chronic Lymphocytic Leukemia
CAR T-Cell Therapy
Bispecific Antibodies
Follicular Lymphoma
Venetoclax
Non-Hodgkin Lymphoma
BTK Inhibitors
Myelofibrosis
Clinical Trials
Diffuse Large B-Cell Lymphoma
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Immune Thrombocytopenia
CAR T Therapy
Mantle Cell Lymphoma
Daratumumab
FDA Approval
Cytokine Release Syndrome
Tyrosine Kinase Inhibitors

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

PublishesTwice weeklyEpisodes545Founded18 years ago
Number of ListenersCategories
ScienceHealth & FitnessMedicine

Listen to this Podcast

Artwork for Hematologic Oncology Update

Latest Episodes

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

• Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL)... more

YouTube

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

• Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)

• Feasibility of disconti... more

YouTube

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:

• Introduction (0:00)

• New and Emerging Strategies with Bispecific Antibodi... more

YouTube

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

• Introduction (0:00)

• Minimal Residual Disease Assays in Community-Based Practice (1:24)

• New Developments in Previously Untreated Chronic ... more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc Docs
Two Onc DocsSam and Karine
Blood Cancer Talks
Blood Cancer TalksRajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Blood Podcast
Blood PodcastAmerican Society of Hematology
NEJM This Week
NEJM This WeekNEJM Group

Recent Guests

Catherine Coombs
Hematologic oncologist at UCI Health
UCI Health
Episode: Chronic Lymphocytic Leukemia — Microlearning Activity 2
Noopur Raje
Director of the Center for Multiple Myeloma and Plasma Cell Disorders at Massachusetts General Brigham Cancer Institute
Massachusetts General Brigham Cancer Institute
Episode: Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Meletios-Athanasios (Thanos) C Dimopoulos
Professor and Chair of the Plasma Cell Unit at the National and Kapodistrian University of Athens
National and Kapodistrian University of Athens
Episode: Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Elizabeth Budde
Medical oncologist, City of Hope National Medical Center
City of Hope National Medical Center
Episode: Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Ann LaCasce
Expert in hematologic malignancies
Dana-Farber/Brigham and Women's Cancer Center
Episode: Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Farrukh Awan
Distinguished faculty from UT Southwestern
Harold Simmons Comprehensive Cancer Center, UT Southwestern
Episode: Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Brad Kahl
Dr. Brad S. Kahl, Washington University School of Medicine/Sightman Cancer Center
Washington University School of Medicine
Episode: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Jeff Sharman
Dr. Jeff Sharman, Sarah Cannon Research Institute at Willamette Valley Cancer Center
Sarah Cannon Research Institute
Episode: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Tanya Siddiqi
Dr. Tanya Siddiqi, City of Hope
City of Hope
Episode: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress

Host

Dr. Neil Love
Host introducing and guiding the interview and discussion; central figure behind the series

Reviews

4.6 out of 5 stars from 134 ratings
  • A favorite of mine

    Podcast Addict
    5
    ZGDave
    3 months ago
  • A debt of gratitude that cannot be repaid

    That is how I feel about Dr Neil Love and his tireless work in continuing medical education for everyone in the medical field. These podcasts and discussions contained are informative, thought provoking and provide and excellent in depth but quick update in the rapidly ever-changing field of Hematology-Oncology.

    Apple Podcasts
    5
    Bongir
    United States4 years ago
  • Excellent content

    Always informative, always applies to those of us on the ground making difficult daily decisions on management in the community. Often with limited resources.

    Apple Podcasts
    5
    ZomBucker
    United States5 years ago
  • Excellent up to date reviews.

    I

    Apple Podcasts
    5
    IanMack5000
    United States15 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Listeners praise the depth and relevance for practicing clinicians.
Guests provide a broad spectrum of expert opinions from top cancer centers.
Audience notes timely updates and practical management insights for community practice.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#78
Saudi Arabia/Science
Apple Podcasts
#110
Argentina/Science
Apple Podcasts
#193
Brazil/Science
Apple Podcasts
#207
China/Science
Apple Podcasts
#240
South Africa/Science

Talking Points

Recent interactions between the hosts and their guests.

Chronic Lymphocytic Leukemia — Microlearning Activity 1
Q: What were your thoughts about this paper and this basic idea of holding a BTK inhibitor just to give the patients a vacation?
Coombs says patients often ask to stop indefinite BTK inhibitor therapy, but prospective evidence is limited. She generally recommends at least two years of treatment and a clinical response before considering discontinuation, and supports randomized trials to establish whether treatment breaks are beneficial.
Chronic Lymphocytic Leukemia — Microlearning Activity 1
Q: In terms of whether or not to actually utilize the delayed Obinutuzumab, would you factor in how the patient's responding?
Coombs would be more likely to add obinutuzumab for patients with unmutated IGHV and less likely for those with mutated IGHV, who may do well without additional treatment. She may still consider it for autoimmune manifestations such as autoimmune cytopenias.
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Q: What's your approach to sequencing Talquatumab relative to other BCMA targeted bispecifics or maybe other BCMA therapies in general, like CAR T cells and antibody drug conjugates?
Raje generally uses BCMA-targeted treatments before talquetamab because of its toxicity profile, while noting that the different target can make either sequence reasonable. For very high-risk patients, she considers combining talquetamab with an anti-BCMA bispecific.
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Q: For which patients are you thinking about using Tecdara, or do you still in some cases like to do bispecific antibody monotherapy, and tell us a little bit about what you're thinking in terms of sequencing?
Raje considers the teclistamab-daratumumab combination appropriate for patients previously exposed to daratumumab who have been off it for a while. For very old or frail patients, she may use bispecific antibody monotherapy.
Chronic Lymphocytic Leukemia — Microlearning Activity 2
Q: Where are we today? But where is allo nowadays? And what about CAR-T, and which CAR-T prep?
Coombs considers CAR T-cell therapy reasonable after failure of a covalent BTK inhibitor or venetoclax, particularly when pirtobrutinib can be used as bridging therapy. She generally favors CAR T-cell therapy before allogeneic transplantation because it is likely safer, while retaining transplantation as a consideration for Richter's transformation.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Hematologic Oncology Update

What is Hematologic Oncology Update about and what kind of topics does it cover?

Hematologic Oncology Update presents expert-driven, case-based discussions analyzing cutting-edge hematologic cancer therapies. Episodes frequently center on real-world sequencing of CAR T cells, bispecific antibodies, BTK inhibitors, and venetoclax-based regimens, with practical insights on toxicity management, patient selection, and care pathways across community and academic settings. The show often features multidisciplinary panels, live case discussions, and national meeting data interpretations from leading cancer centers, making it valuable for clinicians seeking actionable guidance and up-to-date trial context. A notable strength is the long-running, interview-led format that translates complex trial data into clinical decision-maki... more

Where can I find podcast stats for Hematologic Oncology Update?

Rephonic provides a wide range of podcast stats for Hematologic Oncology Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Hematologic Oncology Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Hematologic Oncology Update get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for Hematologic Oncology Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Hematologic Oncology Update?

Rephonic provides comprehensive predictive audience data for Hematologic Oncology Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Hematologic Oncology Update have?

To see how many followers or subscribers Hematologic Oncology Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Hematologic Oncology Update?

These podcasts share a similar audience with Hematologic Oncology Update:

1. Two Onc Docs
2. Blood Cancer Talks
3. Blood Podcast
4. NEJM This Week
5. JAMA Clinical Reviews

How many episodes of Hematologic Oncology Update are there?

Hematologic Oncology Update launched 18 years ago and published 545 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Hematologic Oncology Update?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Hematologic Oncology Update?

Rephonic pulls ratings and reviews for Hematologic Oncology Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Hematologic Oncology Update?

Rephonic provides full transcripts for episodes of Hematologic Oncology Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Hematologic Oncology Update?

Recent guests on Hematologic Oncology Update include:

1. Catherine Coombs
2. Noopur Raje
3. Meletios-Athanasios (Thanos) C Dimopoulos
4. Elizabeth Budde
5. Ann LaCasce
6. Farrukh Awan
7. Brad Kahl
8. Jeff Sharman

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days